Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ACHN

Achillion Pharmaceuticals (ACHN) Stock Price, News & Analysis

Achillion Pharmaceuticals logo

About Achillion Pharmaceuticals Stock (NASDAQ:ACHN)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$0.79
$0.80
50-Day Range
$6.76
$6.76
52-Week Range
$2.06
$7.01
Volume
1,910 shs
Average Volume
8.44 million shs
Market Capitalization
$110.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trials; and ACH-5548, a factor D inhibitor, which is in Phase I clinical trials for the treatment of PNH and other complement mediated diseases. It has license agreements with Ora, Inc. for the development and commercialization of ACH-702; and GCA Therapeutics, Ltd for elvucitabine, a nucleoside reverse transcriptase inhibitor for the treatment of hepatitis B infection and human immunodeficiency virus infection. The company was founded in 1998 and is based in New Haven, Connecticut.

Remove Ads
Receive ACHN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Achillion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACHN Stock News Headlines

Kim P. Kamdar's Net Worth
Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
ACHN_old Historical Data
See More Headlines

ACHN Stock Analysis - Frequently Asked Questions

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) released its quarterly earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.02.

Based on aggregate information from My MarketBeat watchlists, some other companies that Achillion Pharmaceuticals investors own include Chesapeake Energy (CHKAQ), Skyworks Solutions (SWKS), Madrigal Pharmaceuticals (MDGL), Noble (NEBLQ), Gilead Sciences (GILD), Eiger BioPharmaceuticals (EIGR) and Meta Platforms (META).

Company Calendar

Last Earnings
11/07/2019
Today
4/03/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ACHN
Fax
N/A
Employees
56
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-70,270,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$1.92 per share
Price / Book
0.41

Miscellaneous

Free Float
N/A
Market Cap
$110.80 million
Optionable
Optionable
Beta
1.59
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:ACHN) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners